Previous Close | 0.9000 |
Open | 0.8600 |
Bid | 0.8500 x 0 |
Ask | 0.9100 x 0 |
Day's Range | 0.8300 - 0.8600 |
52 Week Range | 0.2500 - 1.6000 |
Volume | 26,220 |
Avg. Volume | 46,867 |
Market Cap | 119.963M |
Beta (5Y Monthly) | -0.17 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0550 |
Earnings Date | Mar. 16, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.10 |
RICHMOND HILL, ON / ACCESSWIRE / April 9, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend the exercise period of a total of 2,837,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm's length parties.
RICHMOND HILL, ON / ACCESSWIRE / March 16, 2021 / Helix BioPharma Corp. (TSX:"HBP"), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2021.
RICHMOND HILL, ON / ACCESSWIRE / February 16, 2021 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr.